# Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

Source: https://onco.cc/trials/nct05607420/  
OnCo record `nct05607420` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Alemtuzumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Cellectis S.A., now recruiting.

## Summary

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT05607420 by Cellectis S.A., with 80 participants planned, started 2022-11-01 and due to reach its primary completion in 2027-08. Interventions recorded: UCART20x22, CLLS52. Conditions listed: B-cell Non-Hodgkin Lymphoma (B-NHL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05607420
- Phase: 1/2
- Setting: Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)
- Sponsor: Cellectis S.A.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT05607420: https://clinicaltrials.gov/study/NCT05607420

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Alemtuzumab](https://onco.cc/drugs/alemtuzumab/)
- companies: [Cellectis S.A.](https://onco.cc/companies/cellectis-s-a/)

---
JSON: https://onco.cc/api/v1/entities/nct05607420.json